Metagenomi, Inc. Common Stock
Metagenomi, Inc. Common Stock (MGX) Stock Competitors & Peer Comparison
See (MGX) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| MGX | $1.60 | +8.11% | 60.1M | -0.67 | -$2.39 | N/A |
| VRTX | $460.87 | +0.92% | 117.1B | 30.12 | $15.30 | N/A |
| REGN | $781.60 | +2.86% | 81.2B | 18.84 | $41.49 | +0.46% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $740.40 | +3.15% | 45.8B | 37.80 | $19.60 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ALNY | $323.59 | +0.91% | 42.9B | 138.26 | $2.34 | N/A |
| INSM | $143.13 | +2.14% | 30.9B | -22.30 | -$6.42 | N/A |
| BNTX | $102.16 | +0.65% | 24.6B | -36.90 | -$2.77 | N/A |
| UTHR | $529.17 | +10.67% | 23.2B | 18.99 | $27.86 | N/A |
Stock Comparison
MGX vs VRTX Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, VRTX has a market cap of 117.1B. Regarding current trading prices, MGX is priced at $1.60, while VRTX trades at $460.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas VRTX's P/E ratio is 30.12. In terms of profitability, MGX's ROE is -0.47%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, MGX is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check VRTX's competition here
MGX vs REGN Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, REGN has a market cap of 81.2B. Regarding current trading prices, MGX is priced at $1.60, while REGN trades at $781.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas REGN's P/E ratio is 18.84. In terms of profitability, MGX's ROE is -0.47%, compared to REGN's ROE of +0.15%. Regarding short-term risk, MGX is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check REGN's competition here
MGX vs VRNA Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, MGX is priced at $1.60, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas VRNA's P/E ratio is -102.80. In terms of profitability, MGX's ROE is -0.47%, compared to VRNA's ROE of -0.30%. Regarding short-term risk, MGX is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check VRNA's competition here
MGX vs ARGX Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, ARGX has a market cap of 45.8B. Regarding current trading prices, MGX is priced at $1.60, while ARGX trades at $740.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas ARGX's P/E ratio is 37.80. In terms of profitability, MGX's ROE is -0.47%, compared to ARGX's ROE of +0.34%. Regarding short-term risk, MGX is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check ARGX's competition here
MGX vs SGEN Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, MGX is priced at $1.60, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas SGEN's P/E ratio is -57.19. In terms of profitability, MGX's ROE is -0.47%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, MGX is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check SGEN's competition here
MGX vs ALNY Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, ALNY has a market cap of 42.9B. Regarding current trading prices, MGX is priced at $1.60, while ALNY trades at $323.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas ALNY's P/E ratio is 138.26. In terms of profitability, MGX's ROE is -0.47%, compared to ALNY's ROE of +0.90%. Regarding short-term risk, MGX is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check ALNY's competition here
MGX vs INSM Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, INSM has a market cap of 30.9B. Regarding current trading prices, MGX is priced at $1.60, while INSM trades at $143.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas INSM's P/E ratio is -22.30. In terms of profitability, MGX's ROE is -0.47%, compared to INSM's ROE of -1.68%. Regarding short-term risk, MGX is more volatile compared to INSM. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check INSM's competition here
MGX vs BNTX Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, BNTX has a market cap of 24.6B. Regarding current trading prices, MGX is priced at $1.60, while BNTX trades at $102.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas BNTX's P/E ratio is -36.90. In terms of profitability, MGX's ROE is -0.47%, compared to BNTX's ROE of -0.03%. Regarding short-term risk, MGX is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check BNTX's competition here
MGX vs UTHR Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, UTHR has a market cap of 23.2B. Regarding current trading prices, MGX is priced at $1.60, while UTHR trades at $529.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas UTHR's P/E ratio is 18.99. In terms of profitability, MGX's ROE is -0.47%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, MGX is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check UTHR's competition here
MGX vs MRNA Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, MRNA has a market cap of 22B. Regarding current trading prices, MGX is priced at $1.60, while MRNA trades at $55.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas MRNA's P/E ratio is -7.68. In terms of profitability, MGX's ROE is -0.47%, compared to MRNA's ROE of -0.30%. Regarding short-term risk, MGX is more volatile compared to MRNA. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check MRNA's competition here
MGX vs ROIV Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, ROIV has a market cap of 21.1B. Regarding current trading prices, MGX is priced at $1.60, while ROIV trades at $29.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas ROIV's P/E ratio is -25.24. In terms of profitability, MGX's ROE is -0.47%, compared to ROIV's ROE of -0.18%. Regarding short-term risk, MGX is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check ROIV's competition here
MGX vs BGNE Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, MGX is priced at $1.60, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas BGNE's P/E ratio is -22.55. In terms of profitability, MGX's ROE is -0.47%, compared to BGNE's ROE of +0.07%. Regarding short-term risk, MGX is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check BGNE's competition here
MGX vs RVMD Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, RVMD has a market cap of 19.8B. Regarding current trading prices, MGX is priced at $1.60, while RVMD trades at $99.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas RVMD's P/E ratio is -16.77. In terms of profitability, MGX's ROE is -0.47%, compared to RVMD's ROE of -0.63%. Regarding short-term risk, MGX is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check RVMD's competition here
MGX vs RPRX Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, RPRX has a market cap of 19.6B. Regarding current trading prices, MGX is priced at $1.60, while RPRX trades at $45.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas RPRX's P/E ratio is 25.75. In terms of profitability, MGX's ROE is -0.47%, compared to RPRX's ROE of +0.12%. Regarding short-term risk, MGX is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check RPRX's competition here
MGX vs INCY Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, INCY has a market cap of 19.3B. Regarding current trading prices, MGX is priced at $1.60, while INCY trades at $97.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas INCY's P/E ratio is 15.15. In terms of profitability, MGX's ROE is -0.47%, compared to INCY's ROE of +0.29%. Regarding short-term risk, MGX is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check INCY's competition here
MGX vs DNA-WT Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, MGX is priced at $1.60, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, MGX's ROE is -0.47%, compared to DNA-WT's ROE of -0.54%. Regarding short-term risk, MGX is more volatile compared to DNA-WT. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check DNA-WT's competition here
MGX vs GMAB Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, GMAB has a market cap of 16.8B. Regarding current trading prices, MGX is priced at $1.60, while GMAB trades at $27.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas GMAB's P/E ratio is 17.70. In terms of profitability, MGX's ROE is -0.47%, compared to GMAB's ROE of +0.11%. Regarding short-term risk, MGX is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check GMAB's competition here
MGX vs ASND Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, ASND has a market cap of 14.7B. Regarding current trading prices, MGX is priced at $1.60, while ASND trades at $239.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas ASND's P/E ratio is -55.07. In terms of profitability, MGX's ROE is -0.47%, compared to ASND's ROE of +1.28%. Regarding short-term risk, MGX is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check ASND's competition here
MGX vs BBIO Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, BBIO has a market cap of 12.7B. Regarding current trading prices, MGX is priced at $1.60, while BBIO trades at $65.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas BBIO's P/E ratio is -17.37. In terms of profitability, MGX's ROE is -0.47%, compared to BBIO's ROE of +0.39%. Regarding short-term risk, MGX is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check BBIO's competition here
MGX vs KRTX Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, MGX is priced at $1.60, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas KRTX's P/E ratio is -28.09. In terms of profitability, MGX's ROE is -0.47%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, MGX is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check KRTX's competition here
MGX vs IONS Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, IONS has a market cap of 12.5B. Regarding current trading prices, MGX is priced at $1.60, while IONS trades at $75.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas IONS's P/E ratio is -31.67. In terms of profitability, MGX's ROE is -0.47%, compared to IONS's ROE of -0.69%. Regarding short-term risk, MGX is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check IONS's competition here
MGX vs BMRN Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, BMRN has a market cap of 11.7B. Regarding current trading prices, MGX is priced at $1.60, while BMRN trades at $60.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas BMRN's P/E ratio is 33.82. In terms of profitability, MGX's ROE is -0.47%, compared to BMRN's ROE of +0.06%. Regarding short-term risk, MGX is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check BMRN's competition here
MGX vs SMMT Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, SMMT has a market cap of 11.7B. Regarding current trading prices, MGX is priced at $1.60, while SMMT trades at $15.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas SMMT's P/E ratio is -10.92. In terms of profitability, MGX's ROE is -0.47%, compared to SMMT's ROE of -2.97%. Regarding short-term risk, MGX is more volatile compared to SMMT. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check SMMT's competition here
MGX vs JAZZ Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, JAZZ has a market cap of 11.4B. Regarding current trading prices, MGX is priced at $1.60, while JAZZ trades at $185.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas JAZZ's P/E ratio is -31.76. In terms of profitability, MGX's ROE is -0.47%, compared to JAZZ's ROE of -0.09%. Regarding short-term risk, MGX is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check JAZZ's competition here
MGX vs EXEL Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, EXEL has a market cap of 11.4B. Regarding current trading prices, MGX is priced at $1.60, while EXEL trades at $42.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas EXEL's P/E ratio is 15.24. In terms of profitability, MGX's ROE is -0.47%, compared to EXEL's ROE of +0.37%. Regarding short-term risk, MGX is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check EXEL's competition here
MGX vs RNAM Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, MGX is priced at $1.60, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas RNAM's P/E ratio is -17.39. In terms of profitability, MGX's ROE is -0.47%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, MGX is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check RNAM's competition here
MGX vs MDGL Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, MDGL has a market cap of 9.8B. Regarding current trading prices, MGX is priced at $1.60, while MDGL trades at $433.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas MDGL's P/E ratio is -33.69. In terms of profitability, MGX's ROE is -0.47%, compared to MDGL's ROE of -0.44%. Regarding short-term risk, MGX is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check MDGL's competition here
MGX vs RXDX Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, MGX is priced at $1.60, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas RXDX's P/E ratio is -56.47. In terms of profitability, MGX's ROE is -0.47%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, MGX is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check RXDX's competition here
MGX vs IMGN Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, MGX is priced at $1.60, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas IMGN's P/E ratio is -111.55. In terms of profitability, MGX's ROE is -0.47%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, MGX is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check IMGN's competition here
MGX vs IBRX Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, IBRX has a market cap of 8.7B. Regarding current trading prices, MGX is priced at $1.60, while IBRX trades at $8.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas IBRX's P/E ratio is -22.22. In terms of profitability, MGX's ROE is -0.47%, compared to IBRX's ROE of +0.64%. Regarding short-term risk, MGX is more volatile compared to IBRX. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check IBRX's competition here
MGX vs TECH Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, TECH has a market cap of 8.6B. Regarding current trading prices, MGX is priced at $1.60, while TECH trades at $54.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas TECH's P/E ratio is 103.53. In terms of profitability, MGX's ROE is -0.47%, compared to TECH's ROE of +0.04%. Regarding short-term risk, MGX is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check TECH's competition here
MGX vs PCVX Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, PCVX has a market cap of 8.5B. Regarding current trading prices, MGX is priced at $1.60, while PCVX trades at $59.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas PCVX's P/E ratio is -10.54. In terms of profitability, MGX's ROE is -0.47%, compared to PCVX's ROE of -0.26%. Regarding short-term risk, MGX is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check PCVX's competition here
MGX vs ARWR Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, ARWR has a market cap of 8.5B. Regarding current trading prices, MGX is priced at $1.60, while ARWR trades at $60.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas ARWR's P/E ratio is 37.94. In terms of profitability, MGX's ROE is -0.47%, compared to ARWR's ROE of +0.36%. Regarding short-term risk, MGX is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check ARWR's competition here
MGX vs AXSM Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, AXSM has a market cap of 8.4B. Regarding current trading prices, MGX is priced at $1.60, while AXSM trades at $164.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas AXSM's P/E ratio is -44.71. In terms of profitability, MGX's ROE is -0.47%, compared to AXSM's ROE of -2.54%. Regarding short-term risk, MGX is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check AXSM's competition here
MGX vs BPMC Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, MGX is priced at $1.60, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas BPMC's P/E ratio is -51.58. In terms of profitability, MGX's ROE is -0.47%, compared to BPMC's ROE of -0.33%. Regarding short-term risk, MGX is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check BPMC's competition here
MGX vs CERE Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, MGX is priced at $1.60, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas CERE's P/E ratio is -16.47. In terms of profitability, MGX's ROE is -0.47%, compared to CERE's ROE of -0.72%. Regarding short-term risk, MGX is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check CERE's competition here
MGX vs HALO Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, HALO has a market cap of 8B. Regarding current trading prices, MGX is priced at $1.60, while HALO trades at $68.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas HALO's P/E ratio is 26.62. In terms of profitability, MGX's ROE is -0.47%, compared to HALO's ROE of +0.93%. Regarding short-term risk, MGX is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check HALO's competition here
MGX vs CYTK Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, CYTK has a market cap of 7.6B. Regarding current trading prices, MGX is priced at $1.60, while CYTK trades at $62.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas CYTK's P/E ratio is -9.54. In terms of profitability, MGX's ROE is -0.47%, compared to CYTK's ROE of +1.73%. Regarding short-term risk, MGX is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check CYTK's competition here
MGX vs KRYS Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, KRYS has a market cap of 7.6B. Regarding current trading prices, MGX is priced at $1.60, while KRYS trades at $258.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas KRYS's P/E ratio is 37.74. In terms of profitability, MGX's ROE is -0.47%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, MGX is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check KRYS's competition here
MGX vs NUVL Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, NUVL has a market cap of 7.5B. Regarding current trading prices, MGX is priced at $1.60, while NUVL trades at $102.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas NUVL's P/E ratio is -17.49. In terms of profitability, MGX's ROE is -0.47%, compared to NUVL's ROE of -0.42%. Regarding short-term risk, MGX is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check NUVL's competition here
MGX vs MTSR Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, MGX is priced at $1.60, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas MTSR's P/E ratio is -23.58. In terms of profitability, MGX's ROE is -0.47%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, MGX is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check MTSR's competition here
MGX vs ABVX Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, ABVX has a market cap of 7.2B. Regarding current trading prices, MGX is priced at $1.60, while ABVX trades at $109.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas ABVX's P/E ratio is -21.28. In terms of profitability, MGX's ROE is -0.47%, compared to ABVX's ROE of +50.78%. Regarding short-term risk, MGX is more volatile compared to ABVX. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check ABVX's competition here
MGX vs KYMR Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, KYMR has a market cap of 6.9B. Regarding current trading prices, MGX is priced at $1.60, while KYMR trades at $85.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas KYMR's P/E ratio is -23.05. In terms of profitability, MGX's ROE is -0.47%, compared to KYMR's ROE of -0.29%. Regarding short-term risk, MGX is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check KYMR's competition here
MGX vs MRUS Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, MGX is priced at $1.60, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas MRUS's P/E ratio is -17.05. In terms of profitability, MGX's ROE is -0.47%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, MGX is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check MRUS's competition here
MGX vs BLTE Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, BLTE has a market cap of 6.7B. Regarding current trading prices, MGX is priced at $1.60, while BLTE trades at $179.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas BLTE's P/E ratio is -93.44. In terms of profitability, MGX's ROE is -0.47%, compared to BLTE's ROE of -0.34%. Regarding short-term risk, MGX is more volatile compared to BLTE. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check BLTE's competition here
MGX vs ACLX Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, MGX is priced at $1.60, while ACLX trades at $114.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas ACLX's P/E ratio is -28.13. In terms of profitability, MGX's ROE is -0.47%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, MGX is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check ACLX's competition here
MGX vs RETA Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, MGX is priced at $1.60, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas RETA's P/E ratio is -66.29. In terms of profitability, MGX's ROE is -0.47%, compared to RETA's ROE of +0.47%. Regarding short-term risk, MGX is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check RETA's competition here
MGX vs PRAX Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, PRAX has a market cap of 6.5B. Regarding current trading prices, MGX is priced at $1.60, while PRAX trades at $309.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas PRAX's P/E ratio is -22.94. In terms of profitability, MGX's ROE is -0.47%, compared to PRAX's ROE of -0.59%. Regarding short-term risk, MGX is less volatile compared to PRAX. This indicates potentially lower risk in terms of short-term price fluctuations for MGX.Check PRAX's competition here
MGX vs RYTM Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, RYTM has a market cap of 6.4B. Regarding current trading prices, MGX is priced at $1.60, while RYTM trades at $93.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas RYTM's P/E ratio is -29.90. In terms of profitability, MGX's ROE is -0.47%, compared to RYTM's ROE of -1.79%. Regarding short-term risk, MGX is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check RYTM's competition here
MGX vs PTGX Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, PTGX has a market cap of 6.2B. Regarding current trading prices, MGX is priced at $1.60, while PTGX trades at $96.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas PTGX's P/E ratio is -47.15. In terms of profitability, MGX's ROE is -0.47%, compared to PTGX's ROE of -0.20%. Regarding short-term risk, MGX is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check PTGX's competition here
MGX vs COGT Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, COGT has a market cap of 6B. Regarding current trading prices, MGX is priced at $1.60, while COGT trades at $37.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas COGT's P/E ratio is -17.13. In terms of profitability, MGX's ROE is -0.47%, compared to COGT's ROE of -1.00%. Regarding short-term risk, MGX is more volatile compared to COGT. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check COGT's competition here
MGX vs PTCT Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, PTCT has a market cap of 5.7B. Regarding current trading prices, MGX is priced at $1.60, while PTCT trades at $68.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas PTCT's P/E ratio is 7.97. In terms of profitability, MGX's ROE is -0.47%, compared to PTCT's ROE of -3.62%. Regarding short-term risk, MGX is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check PTCT's competition here
MGX vs CRSP Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, CRSP has a market cap of 5.6B. Regarding current trading prices, MGX is priced at $1.60, while CRSP trades at $58.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas CRSP's P/E ratio is -9.09. In terms of profitability, MGX's ROE is -0.47%, compared to CRSP's ROE of -0.32%. Regarding short-term risk, MGX is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check CRSP's competition here
MGX vs CDTX Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, MGX is priced at $1.60, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas CDTX's P/E ratio is -19.77. In terms of profitability, MGX's ROE is -0.47%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, MGX is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check CDTX's competition here
MGX vs ABCM Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, MGX is priced at $1.60, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, MGX's ROE is -0.47%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, MGX is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check ABCM's competition here
MGX vs ISEE Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, MGX is priced at $1.60, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas ISEE's P/E ratio is -22.44. In terms of profitability, MGX's ROE is -0.47%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, MGX is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check ISEE's competition here
MGX vs IMVT Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, IMVT has a market cap of 5.4B. Regarding current trading prices, MGX is priced at $1.60, while IMVT trades at $26.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas IMVT's P/E ratio is -9.88. In terms of profitability, MGX's ROE is -0.47%, compared to IMVT's ROE of -0.66%. Regarding short-term risk, MGX is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check IMVT's competition here
MGX vs CAI Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, CAI has a market cap of 5.4B. Regarding current trading prices, MGX is priced at $1.60, while CAI trades at $19.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas CAI's P/E ratio is -5.39. In terms of profitability, MGX's ROE is -0.47%, compared to CAI's ROE of +1.97%. Regarding short-term risk, MGX is more volatile compared to CAI. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check CAI's competition here
MGX vs FBIOX Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, FBIOX has a market cap of 5.4B. Regarding current trading prices, MGX is priced at $1.60, while FBIOX trades at $25.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas FBIOX's P/E ratio is N/A. In terms of profitability, MGX's ROE is -0.47%, compared to FBIOX's ROE of +0.00%. Regarding short-term risk, MGX is more volatile compared to FBIOX. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check FBIOX's competition here
MGX vs CELC Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, CELC has a market cap of 5.3B. Regarding current trading prices, MGX is priced at $1.60, while CELC trades at $113.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas CELC's P/E ratio is -30.89. In terms of profitability, MGX's ROE is -0.47%, compared to CELC's ROE of -1.79%. Regarding short-term risk, MGX is more volatile compared to CELC. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check CELC's competition here
MGX vs CGON Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, CGON has a market cap of 5.2B. Regarding current trading prices, MGX is priced at $1.60, while CGON trades at $61.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas CGON's P/E ratio is -29.46. In terms of profitability, MGX's ROE is -0.47%, compared to CGON's ROE of -0.23%. Regarding short-term risk, MGX is more volatile compared to CGON. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check CGON's competition here
MGX vs ERAS Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, ERAS has a market cap of 4.9B. Regarding current trading prices, MGX is priced at $1.60, while ERAS trades at $15.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas ERAS's P/E ratio is -36.65. In terms of profitability, MGX's ROE is -0.47%, compared to ERAS's ROE of -0.33%. Regarding short-term risk, MGX is more volatile compared to ERAS. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check ERAS's competition here
MGX vs XENE Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, XENE has a market cap of 4.8B. Regarding current trading prices, MGX is priced at $1.60, while XENE trades at $62.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas XENE's P/E ratio is -16.13. In terms of profitability, MGX's ROE is -0.47%, compared to XENE's ROE of -0.56%. Regarding short-term risk, MGX is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check XENE's competition here
MGX vs ALKS Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, ALKS has a market cap of 4.7B. Regarding current trading prices, MGX is priced at $1.60, while ALKS trades at $28.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas ALKS's P/E ratio is 19.89. In terms of profitability, MGX's ROE is -0.47%, compared to ALKS's ROE of +0.14%. Regarding short-term risk, MGX is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check ALKS's competition here
MGX vs TGTX Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, TGTX has a market cap of 4.7B. Regarding current trading prices, MGX is priced at $1.60, while TGTX trades at $29.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas TGTX's P/E ratio is 10.54. In terms of profitability, MGX's ROE is -0.47%, compared to TGTX's ROE of +1.01%. Regarding short-term risk, MGX is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check TGTX's competition here
MGX vs FOLD Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, MGX is priced at $1.60, while FOLD trades at $14.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas FOLD's P/E ratio is -159.67. In terms of profitability, MGX's ROE is -0.47%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, MGX is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check FOLD's competition here
MGX vs SRRK Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, SRRK has a market cap of 4.5B. Regarding current trading prices, MGX is priced at $1.60, while SRRK trades at $44.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas SRRK's P/E ratio is -14.04. In terms of profitability, MGX's ROE is -0.47%, compared to SRRK's ROE of -1.46%. Regarding short-term risk, MGX is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check SRRK's competition here
MGX vs AKRO Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, MGX is priced at $1.60, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas AKRO's P/E ratio is -14.57. In terms of profitability, MGX's ROE is -0.47%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, MGX is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check AKRO's competition here
MGX vs ALPN Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, MGX is priced at $1.60, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas ALPN's P/E ratio is -101.52. In terms of profitability, MGX's ROE is -0.47%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, MGX is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check ALPN's competition here
MGX vs MIRM Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, MIRM has a market cap of 4.5B. Regarding current trading prices, MGX is priced at $1.60, while MIRM trades at $88.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas MIRM's P/E ratio is -188.89. In terms of profitability, MGX's ROE is -0.47%, compared to MIRM's ROE of -0.09%. Regarding short-term risk, MGX is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check MIRM's competition here
MGX vs OPT Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, MGX is priced at $1.60, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas OPT's P/E ratio is -1.52. In terms of profitability, MGX's ROE is -0.47%, compared to OPT's ROE of +0.88%. Regarding short-term risk, MGX is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check OPT's competition here
MGX vs LGND Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, LGND has a market cap of 4.1B. Regarding current trading prices, MGX is priced at $1.60, while LGND trades at $208.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas LGND's P/E ratio is 33.84. In terms of profitability, MGX's ROE is -0.47%, compared to LGND's ROE of +0.14%. Regarding short-term risk, MGX is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check LGND's competition here
MGX vs MRTX Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, MGX is priced at $1.60, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas MRTX's P/E ratio is -4.82. In terms of profitability, MGX's ROE is -0.47%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, MGX is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check MRTX's competition here
MGX vs APGE Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, APGE has a market cap of 4.1B. Regarding current trading prices, MGX is priced at $1.60, while APGE trades at $74.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas APGE's P/E ratio is -17.13. In terms of profitability, MGX's ROE is -0.47%, compared to APGE's ROE of -0.37%. Regarding short-term risk, MGX is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check APGE's competition here
MGX vs CRNX Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, CRNX has a market cap of 4B. Regarding current trading prices, MGX is priced at $1.60, while CRNX trades at $38.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas CRNX's P/E ratio is -7.72. In terms of profitability, MGX's ROE is -0.47%, compared to CRNX's ROE of -0.41%. Regarding short-term risk, MGX is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check CRNX's competition here
MGX vs TERN Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, TERN has a market cap of 4B. Regarding current trading prices, MGX is priced at $1.60, while TERN trades at $44.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas TERN's P/E ratio is -43.42. In terms of profitability, MGX's ROE is -0.47%, compared to TERN's ROE of -0.30%. Regarding short-term risk, MGX is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check TERN's competition here
MGX vs VKTX Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, VKTX has a market cap of 3.9B. Regarding current trading prices, MGX is priced at $1.60, while VKTX trades at $33.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas VKTX's P/E ratio is -10.54. In terms of profitability, MGX's ROE is -0.47%, compared to VKTX's ROE of -0.48%. Regarding short-term risk, MGX is more volatile compared to VKTX. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check VKTX's competition here
MGX vs ACAD Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, ACAD has a market cap of 3.8B. Regarding current trading prices, MGX is priced at $1.60, while ACAD trades at $22.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas ACAD's P/E ratio is 9.82. In terms of profitability, MGX's ROE is -0.47%, compared to ACAD's ROE of +0.42%. Regarding short-term risk, MGX is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check ACAD's competition here
MGX vs ADMA Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, ADMA has a market cap of 3.8B. Regarding current trading prices, MGX is priced at $1.60, while ADMA trades at $15.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas ADMA's P/E ratio is 26.35. In terms of profitability, MGX's ROE is -0.47%, compared to ADMA's ROE of +0.35%. Regarding short-term risk, MGX is more volatile compared to ADMA. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check ADMA's competition here
MGX vs RYZB Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, MGX is priced at $1.60, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas RYZB's P/E ratio is -57.86. In terms of profitability, MGX's ROE is -0.47%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, MGX is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check RYZB's competition here
MGX vs CBAY Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, MGX is priced at $1.60, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas CBAY's P/E ratio is -32.81. In terms of profitability, MGX's ROE is -0.47%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, MGX is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check CBAY's competition here
MGX vs CORT Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, CORT has a market cap of 3.6B. Regarding current trading prices, MGX is priced at $1.60, while CORT trades at $33.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas CORT's P/E ratio is 41.40. In terms of profitability, MGX's ROE is -0.47%, compared to CORT's ROE of +0.15%. Regarding short-term risk, MGX is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check CORT's competition here
MGX vs SWTX Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, MGX is priced at $1.60, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas SWTX's P/E ratio is -13.78. In terms of profitability, MGX's ROE is -0.47%, compared to SWTX's ROE of -0.45%. Regarding short-term risk, MGX is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check SWTX's competition here
MGX vs NAMS Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, NAMS has a market cap of 3.5B. Regarding current trading prices, MGX is priced at $1.60, while NAMS trades at $30.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas NAMS's P/E ratio is -17.89. In terms of profitability, MGX's ROE is -0.47%, compared to NAMS's ROE of -0.27%. Regarding short-term risk, MGX is more volatile compared to NAMS. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check NAMS's competition here
MGX vs CNTA Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, CNTA has a market cap of 3.5B. Regarding current trading prices, MGX is priced at $1.60, while CNTA trades at $26.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas CNTA's P/E ratio is -13.80. In terms of profitability, MGX's ROE is -0.47%, compared to CNTA's ROE of -0.68%. Regarding short-term risk, MGX is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check CNTA's competition here
MGX vs KNSA Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, KNSA has a market cap of 3.5B. Regarding current trading prices, MGX is priced at $1.60, while KNSA trades at $46.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas KNSA's P/E ratio is 62.40. In terms of profitability, MGX's ROE is -0.47%, compared to KNSA's ROE of +0.11%. Regarding short-term risk, MGX is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check KNSA's competition here
MGX vs DNLI Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, DNLI has a market cap of 3.3B. Regarding current trading prices, MGX is priced at $1.60, while DNLI trades at $21.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas DNLI's P/E ratio is -7.30. In terms of profitability, MGX's ROE is -0.47%, compared to DNLI's ROE of -0.50%. Regarding short-term risk, MGX is more volatile compared to DNLI. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check DNLI's competition here
MGX vs GPCR Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, GPCR has a market cap of 3.3B. Regarding current trading prices, MGX is priced at $1.60, while GPCR trades at $56.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas GPCR's P/E ratio is -23.52. In terms of profitability, MGX's ROE is -0.47%, compared to GPCR's ROE of -0.15%. Regarding short-term risk, MGX is more volatile compared to GPCR. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check GPCR's competition here
MGX vs TARS Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, TARS has a market cap of 3.2B. Regarding current trading prices, MGX is priced at $1.60, while TARS trades at $74.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas TARS's P/E ratio is -46.85. In terms of profitability, MGX's ROE is -0.47%, compared to TARS's ROE of -0.20%. Regarding short-term risk, MGX is more volatile compared to TARS. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check TARS's competition here
MGX vs LQDA Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, LQDA has a market cap of 3.1B. Regarding current trading prices, MGX is priced at $1.60, while LQDA trades at $35.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas LQDA's P/E ratio is -24.57. In terms of profitability, MGX's ROE is -0.47%, compared to LQDA's ROE of -2.09%. Regarding short-term risk, MGX is more volatile compared to LQDA. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check LQDA's competition here
MGX vs IDYA Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, IDYA has a market cap of 3.1B. Regarding current trading prices, MGX is priced at $1.60, while IDYA trades at $35.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas IDYA's P/E ratio is -27.38. In terms of profitability, MGX's ROE is -0.47%, compared to IDYA's ROE of -0.11%. Regarding short-term risk, MGX is more volatile compared to IDYA. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check IDYA's competition here
MGX vs ARQT Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, ARQT has a market cap of 3.1B. Regarding current trading prices, MGX is priced at $1.60, while ARQT trades at $24.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas ARQT's P/E ratio is -190.81. In terms of profitability, MGX's ROE is -0.47%, compared to ARQT's ROE of -0.10%. Regarding short-term risk, MGX is more volatile compared to ARQT. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check ARQT's competition here
MGX vs EWTX Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, EWTX has a market cap of 3.1B. Regarding current trading prices, MGX is priced at $1.60, while EWTX trades at $28.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas EWTX's P/E ratio is -17.55. In terms of profitability, MGX's ROE is -0.47%, compared to EWTX's ROE of -0.32%. Regarding short-term risk, MGX is more volatile compared to EWTX. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check EWTX's competition here
MGX vs CPRX Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, CPRX has a market cap of 3B. Regarding current trading prices, MGX is priced at $1.60, while CPRX trades at $24.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas CPRX's P/E ratio is 14.76. In terms of profitability, MGX's ROE is -0.47%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, MGX is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check CPRX's competition here
MGX vs DYN Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, DYN has a market cap of 2.9B. Regarding current trading prices, MGX is priced at $1.60, while DYN trades at $17.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas DYN's P/E ratio is -4.89. In terms of profitability, MGX's ROE is -0.47%, compared to DYN's ROE of -0.61%. Regarding short-term risk, MGX is less volatile compared to DYN. This indicates potentially lower risk in terms of short-term price fluctuations for MGX.Check DYN's competition here
MGX vs DNTH Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, DNTH has a market cap of 2.9B. Regarding current trading prices, MGX is priced at $1.60, while DNTH trades at $79.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas DNTH's P/E ratio is -22.62. In terms of profitability, MGX's ROE is -0.47%, compared to DNTH's ROE of -0.30%. Regarding short-term risk, MGX is more volatile compared to DNTH. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check DNTH's competition here
MGX vs MORF Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, MORF has a market cap of 2.9B. Regarding current trading prices, MGX is priced at $1.60, while MORF trades at $56.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas MORF's P/E ratio is -14.88. In terms of profitability, MGX's ROE is -0.47%, compared to MORF's ROE of -0.29%. Regarding short-term risk, MGX is more volatile compared to MORF. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check MORF's competition here
MGX vs MOR Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, MOR has a market cap of 2.9B. Regarding current trading prices, MGX is priced at $1.60, while MOR trades at $18.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas MOR's P/E ratio is -12.64. In terms of profitability, MGX's ROE is -0.47%, compared to MOR's ROE of -1.84%. Regarding short-term risk, MGX is more volatile compared to MOR. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check MOR's competition here
MGX vs BEAM Comparison March 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 60.1M. In comparison, BEAM has a market cap of 2.8B. Regarding current trading prices, MGX is priced at $1.60, while BEAM trades at $27.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.67, whereas BEAM's P/E ratio is -34.10. In terms of profitability, MGX's ROE is -0.47%, compared to BEAM's ROE of -0.07%. Regarding short-term risk, MGX is more volatile compared to BEAM. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check BEAM's competition here